Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BARDA Lays Out Vision For Next Pandemic: Vaccines For The US Within 130 Days

Executive Summary

Federal agency seeks dialogue with industry on how to enable surge capacity for pandemic vaccines without cutting back on other production.One key factor: workforce development.

You may also be interested in...



For Next Pandemic, BARDA Proposes New Consortia For Rapid Response

HHS agency would expand on DOD consortium approach that delivered the COVID-19 vaccines to bring together private sector teams that could quickly defend the US against future infectious outbreaks. Plan also calls for working with commercial lenders for the capital required to expand production of medical countermeasures.

Achieving A Resilient Flu Vaccine Supply Chain Requires Retooling Most Of The Links

Expert panel draws lessons from COVID-19 in pressing for new manufacturing technologies, greater global coordination, more resilient supply chains and trained vaccine plant workers ready to “parachute” into the next outbreak.

As Emergent Partnership Dissolves, BARDA Looks To Revamp Post-COVID Pandemic Preparedness

BARDA terminates CIADM contract in wake of vaccine cross-contamination incident, begins discussion with industry about next steps for rapid pandemic response capabilities.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145272

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel